Spectris completes £163m acquisition of Concept Life Sciences
Spectris has completed a £163m deal for Concept Life Sciences, a UK-based provider of integrated drug discovery, development, analytical testing and environment consultancy services to the pharmaceutical, biotech, agrochemical and environmental sectors. Spectris is a leading supplier of productivity-enhancing instrumentation and controls. The acquisition adds test service capabilities to its Materials Analysis division, where it has strong synergies with Malvern Panalytical. Spectris expects these markets to continue to grow as a result of increasing regulation and the complexity of pharmaceutical R&D and investments in new therapies.